- Barrons.com•2 hours ago
Vertex Pharmaceuticals gained 20% to $108.01 today, while the S&P 500 ticked up 0.1% to 2,361.13. Morgan Stanley's Matthew Harrison and team write that the data on Vertex's cystic fibrosis treatment was "as good as we could have hoped." They explain: [Last night's] data represent the best case scenario and we see VRTX quickly moving higher as it becomes a key stock to own for the 2H17 triple combination optionality. Vertex Pharmaceuticals' market capitalization rose to $26.8 billion today from $22.3 billion yesterday.
- Reuters•3 hours ago
The benchmark S&P 500 eked out a gain on Wednesday as strength in the energy and consumer sectors offset declines in financial shares and investors began looking ahead to first-quarter earnings season. The Dow Jones Industrial Average ended slightly lower, falling for the ninth session out of the past 10, while the Nasdaq rose for a fourth straight day. Investors have been assessing what the Republicans' failure to pass a healthcare bill means for tax reform and the rest of President Donald Trump's agenda, hopes for which have helped drive stocks to record highs.
- Investor's Business Daily•3 hours ago
Vertex Pharmaceuticals stock rocketed Wednesday after the company unveiled strong cystic fibrosis drug data.
VRTX : Summary for Vertex Pharmaceuticals Incorpor - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
|Bid||108.10 x 100|
|Ask||108.55 x 200|
|Day's Range||106.03 - 111.88|
|52 Week Range||71.46 - 111.88|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-234.80|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|